141 related articles for article (PubMed ID: 23563604)
21. Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across species.
Wang Z; Do CW; Avila MY; Peterson-Yantorno K; Stone RA; Gao ZG; Joshi B; Besada P; Jeong LS; Jacobson KA; Civan MM
Exp Eye Res; 2010 Jan; 90(1):146-54. PubMed ID: 19878673
[TBL] [Abstract][Full Text] [Related]
22. Induction of apoptosis by A3 adenosine receptor agonist N-(3-iodobenzyl)-adenosine-5'-N-methylcarboxamide in human leukaemia cells: a possible involvement of intracellular mechanism.
Mlejnek P; Dolezel P
Acta Physiol (Oxf); 2010 Jun; 199(2):171-9. PubMed ID: 20121715
[TBL] [Abstract][Full Text] [Related]
23. Current and emerging medical therapies in the treatment of glaucoma.
Bagnis A; Papadia M; Scotto R; Traverso CE
Expert Opin Emerg Drugs; 2011 Jun; 16(2):293-307. PubMed ID: 21406029
[TBL] [Abstract][Full Text] [Related]
24. Molecular modeling study on potent and selective adenosine A(3) receptor agonists.
Dal Ben D; Buccioni M; Lambertucci C; Marucci G; Thomas A; Volpini R; Cristalli G
Bioorg Med Chem; 2010 Nov; 18(22):7923-30. PubMed ID: 20943397
[TBL] [Abstract][Full Text] [Related]
25. Uncovering the Mechanisms of Adenosine Receptor-Mediated Pain Control: Focus on the A
Coppi E; Cherchi F; Lucarini E; Ghelardini C; Pedata F; Jacobson KA; Di Cesare Mannelli L; Pugliese AM; Salvemini D
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360719
[TBL] [Abstract][Full Text] [Related]
26. Structure-Activity Analysis of Biased Agonism at the Human Adenosine A3 Receptor.
Baltos JA; Paoletta S; Nguyen AT; Gregory KJ; Tosh DK; Christopoulos A; Jacobson KA; May LT
Mol Pharmacol; 2016 Jul; 90(1):12-22. PubMed ID: 27136943
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101.
Ohana G; Bar-Yehuda S; Arich A; Madi L; Dreznick Z; Rath-Wolfson L; Silberman D; Slosman G; Fishman P
Br J Cancer; 2003 Oct; 89(8):1552-8. PubMed ID: 14562031
[TBL] [Abstract][Full Text] [Related]
28. Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study Data.
Fishman P
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744805
[TBL] [Abstract][Full Text] [Related]
29. Structure-activity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma.
Okamura T; Kurogi Y; Hashimoto K; Sato S; Nishikawa H; Kiryu K; Nagao Y
Bioorg Med Chem Lett; 2004 Jul; 14(14):3775-9. PubMed ID: 15203160
[TBL] [Abstract][Full Text] [Related]
30. [Retinal ganglion cells death in glaucoma--mechanism and potential treatment. Part I].
Rokicki W; Dorecka M; Romaniuk W
Klin Oczna; 2007; 109(7-9):349-52. PubMed ID: 18260296
[TBL] [Abstract][Full Text] [Related]
31. Molecular dissection of the human A
Storme J; Cannaert A; Van Craenenbroeck K; Stove CP
Biochem Pharmacol; 2018 Feb; 148():298-307. PubMed ID: 29309765
[TBL] [Abstract][Full Text] [Related]
32. The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure.
Yang H; Avila MY; Peterson-Yantorno K; Coca-Prados M; Stone RA; Jacobson KA; Civan MM
Curr Eye Res; 2005 Sep; 30(9):747-54. PubMed ID: 16146920
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures.
Hare WA; WoldeMussie E; Weinreb RN; Ton H; Ruiz G; Wijono M; Feldmann B; Zangwill L; Wheeler L
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2640-51. PubMed ID: 15277487
[TBL] [Abstract][Full Text] [Related]
34. Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.
Baraldi PG; Preti D; Borea PA; Varani K
J Med Chem; 2012 Jun; 55(12):5676-703. PubMed ID: 22468757
[No Abstract] [Full Text] [Related]
35. The A3 adenosine receptor: history and perspectives.
Borea PA; Varani K; Vincenzi F; Baraldi PG; Tabrizi MA; Merighi S; Gessi S
Pharmacol Rev; 2015; 67(1):74-102. PubMed ID: 25387804
[TBL] [Abstract][Full Text] [Related]
36. Topically administered timolol and dorzolamide reduce intraocular pressure and protect retinal ganglion cells in a rat experimental glaucoma model.
Seki M; Tanaka T; Matsuda H; Togano T; Hashimoto K; Ueda J; Fukuchi T; Abe H
Br J Ophthalmol; 2005 Apr; 89(4):504-7. PubMed ID: 15774933
[TBL] [Abstract][Full Text] [Related]
37. LJ-529, a partial peroxisome proliferator-activated receptor gamma (PPARγ) agonist and adenosine A
Boo HJ; Park SJ; Noh M; Min HY; Jeong LS; Lee HY
Arch Pharm Res; 2020 May; 43(5):540-552. PubMed ID: 32430718
[TBL] [Abstract][Full Text] [Related]
38. Neuro-protection of retinal stem cells transplantation combined with copolymer-1 immunization in a rat model of glaucoma.
Zhou X; Xia XB; Xiong SQ
Mol Cell Neurosci; 2013 May; 54():1-8. PubMed ID: 23246669
[TBL] [Abstract][Full Text] [Related]
39. Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma.
Yang H; Hirooka K; Fukuda K; Shiraga F
Invest Ophthalmol Vis Sci; 2009 Dec; 50(12):5800-4. PubMed ID: 19608537
[TBL] [Abstract][Full Text] [Related]
40. Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice.
Zhong L; Bradley J; Schubert W; Ahmed E; Adamis AP; Shima DT; Robinson GS; Ng YS
Invest Ophthalmol Vis Sci; 2007 Mar; 48(3):1212-8. PubMed ID: 17325165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
